$CBIS To support its existing CBN patent, the company has delivered pure CBN compound to two research facilities in Europe where testing will be started to establish activity of CBN alone and in combination with other cannabinoids in anxiety, sleep disorders as well as in variety of neurological conditions including Alzheimer's disease.

http://www.stockwatch.com/News/Item.aspx?bid=...BIS®ion=U